AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01061710 — intervention group
Intervention type: DRUG
Intervention: varenicline
Description: Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
Study NCT01287429 — intervention group
Intervention type: OTHER
Intervention: lung and pleural ultrasound
Description: After the initial diagnostic work-out (medical history, physical examination, EKG, arterious blood gas), the emergency physician will classify dyspnoea in cardiogenic or respiratory dyspnoea and write it down in a specific form (clinical form). Immediately after this, lung and pleural ultrasound will be performed: the physician will describe it and evaluate the etiology again (integrated evaluation form). Then a chest X-ray evaluation will be performed for each patient.
Study NCT02104011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study NCT00201773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg orally once per day for 16 weeks.
Study NCT00201773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.
Study NCT00201773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative studies
Study NCT04032327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel plus plain bupivacaine
Description: 10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed to be injected vaginally prior to the start of posterior colporrhaphy
Study NCT04032327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 mL of 0.25% plain bupivacaine to be injected vaginally prior to the start of posterior colporrhaphy
Study NCT03099863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopic Fluid containing Neosporin G. U. Irrigant
Description: Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
Study NCT03099863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy
Description: Diagnostic cystoscopy performed during pelvic floor surgery
Study NCT03099863 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cystoscopy
Description: Diagnostic cystoscopy performed during pelvic floor surgery
Study NCT03937557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: photofinder levicam
Description: Exam frontal, bilateral Temporal and occipital scalp by photofinder levicam and compare the pros and cons with the data from scalp biopsy.
Study NCT03937557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: photofinder levicam
Description: Exam frontal, bilateral Temporal and occipital scalp by photofinder levicam and compare the pros and cons with the data from scalp biopsy.
Study NCT01471067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.
Study NCT01471067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).
Study NCT01471067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.
Study NCT01471067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Infusion
Description: Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.
Study NCT01471067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein on Day -10 for B cell malignancy.
Study NCT01471067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: 1.25 mg/Kg by vein on Day -4.~1.75 mg/Kg by vein on Day -3.
Study NCT01471067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
Study NCT01471067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 30 mg/m\^2 IV Day -7 to Day -4;
Study NCT01471067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 2 Gy in AM of Day -3.
Study NCT03099863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cystoscopic Fluid/Placebo
Description: Normal saline cystoscopic fluid
Study NCT04065256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized music
Description: Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player.
Study NCT04065256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized music plus earplug
Description: Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player. In addition, participants will be worn earplug during night time sleep for decreasing the noise until next morning.
Study NCT02427217 — intervention group
Intervention type: BIOLOGICAL
Intervention: FCH
Description: FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
Study NCT01491932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Description: AFQ056 will be supplied as oral capsules.
Study NCT00026403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00026403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00026403 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03398382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium tablet group
Description: Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-artikain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected, the patient will receive magnesium citrate tablets. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
Study NCT03398382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets group
Description: Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected , the patient will receive placebo tablets which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
Study NCT03398382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium lozenge group
Description: Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX..) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive magnesium citrate lozenge.The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate lozenges. 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
Study NCT03398382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenges group
Description: Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive placebo lozenges which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo lozenges 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
Study NCT00003937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT01845077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2x500 mg Metformin (Glumetza)
Description: 2 tablets
Study NCT01845077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Linagliptin/1000 mg Metformin FDC
Description: FDC tablet
Study NCT01845077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg Linagliptin (Tradjenta)
Description: 1 tablet
Study NCT01845077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3x500 mg Metformin (Glumetza)
Description: 3 tablets
Study NCT01113476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
Study NCT05851001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation exercise
Description: This intervention consists of two parts. The first part (11 minutes) gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are 27 minutes of relaxation exercises accompanied by command with background music.
Study NCT05851001 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Muscle relaxation exercise
Description: The participant was asked to listen to relaxation music for 30 minutes in a private room.
Study NCT02618395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC001A
Study NCT02618395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC001B
Study NCT02618395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference001 - Hydrocodone
Description: Hydrocodone-acetaminophen
Study NCT00180700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Study NCT00746447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine granules
Description: 3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
Study NCT00746447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine granules
Description: 1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
Study NCT00746447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mesalamine granules
Description: 0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
Study NCT03973801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.
Study NCT01845077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 x 500 mg Metformin (Glumetza)
Description: 2 tablets
Study NCT01845077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Linagliptin/1000mg Metformin FDC
Description: FDC Tablet
Study NCT01845077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
Description: 2 FDC tablets
Study NCT01578746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct lateral approach in total hip arthroplasty
Description: The use of direct lateral approach in total hip arthroplasty
Study NCT01578746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior approach
Description: The use of anterior approach in total hip arthroplasty
Study NCT01018056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
Study NCT01018056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
Study NCT01018056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
Study NCT01865071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: loop ileostomi
Study NCT03924271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iron deficiency testing
Description: Blood sample for complete iron status
Study NCT04218682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shadow's Edge Mobile Application Gameplay
Description: 6 weeks of individual, interactive game play of the Shadow's Edge mobile app.
Study NCT01009242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: Single dose:~1 mg/kg CDP6038 IV
Study NCT01009242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: Single dose:~0.1mg/kg CDP6038 IV
Study NCT01009242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: Single dose:~1.0mg/kg CDP6038 SC
Study NCT01009242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Single dose:~Placebo IV
Study NCT01009242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Single dose:~Placebo SC
Study NCT01009242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP 6038 SC
Description: Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo
Study NCT01009242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Individual stable doses of methotrexate.
Study NCT05098236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in the Blind Field
Description: A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. Subjects will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 3 and up to 12 months at a time.
Study NCT05098236 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training in the Sighted Field
Description: This training will take place in lab at the University of Rochester Medical Center. Subject will perform one daily training session, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion, the presence of motion, or the orientation of a visual stimulus (either a small cloud of dots or bars) located at a predetermined location in the visual field. The computer program will automatically create a record of patient performance during each training session. Subjects will train daily (about 30-40 minutes total), 5 to 7 days per week for at 7 - 14 days.
Study NCT04882215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GMT combined with WMU Training
Description: GMT teaches the use of mental strategies to support sustained attention during complex (multi-step) task performance following an interactive programme. GMT is structured into nine modules, with interactive discussions and homework assignments. It will be conducted on a group basis.~WMU training consists of computerised working memory updating tasks in which trial accuracy and response time are recorded. Two tasks will be trained: 1. a visuo-spatial Matrix Updating (MU) and 2. a verbal Keep Track (KT). For both training tasks, level of difficulty can be modulated by increasing or decreasing the update level, i.e., the number of updates on each trial.
Study NCT04882215 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GMT combined with WMU Training
Description: GMT teaches the use of mental strategies to support sustained attention during complex (multi-step) task performance following an interactive programme. GMT is structured into nine modules, with interactive discussions and homework assignments. It will be conducted on a group basis.~WMU training consists of computerised working memory updating tasks in which trial accuracy and response time are recorded. Two tasks will be trained: 1. a visuo-spatial Matrix Updating (MU) and 2. a verbal Keep Track (KT). For both training tasks, level of difficulty can be modulated by increasing or decreasing the update level, i.e., the number of updates on each trial.
Study NCT03225989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOAd703
Description: Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
Study NCT02822755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program and Adherence Logs
Description: Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
Study NCT02822755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program and Adherence Logs
Description: Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
Study NCT03075631 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires
Study NCT04026282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GnRH-ant protocol
Description: Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
Study NCT04026282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GnRH-a long protocol
Description: The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
Study NCT04735900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid biopsy sampling
Description: Biweekly liquid biopsy sampling to measure circulating tumor DNA (ctDNA) level up to and including 9 months after start first-line therapy.